Built for the queries no current tool can answer. Cross-corpus retrieval over the full open biomedical literature, joined by canonical concepts, graded by evidence, tracked across time.
Most biomedical AI tools answer the easy questions. Definitions. Dosages. Summary symptoms. The hard questions, the ones that live across hundreds of papers and require evidence weighting and contradiction tracking, fall through every existing tool. GALEN is engineered for that gap.
GALEN ingests every open-access biomedical paper NIH publishes, every abstract in the PubMed index, every expert-authored review of every genetic condition, every canonical reference textbook in the NCBI Bookshelf, all joined through the medical concept graph.
The data has been free for over a decade. NIH publishes the entire corpus on public infrastructure with explicit reuse licenses. The reason a working version of GALEN does not already exist is not data access. It is the integration: section-aware chunking, concept-graph joins, publication-type evidence weighting, temporal binning, and contradiction surfacing, all wired through a query orchestrator that decides which primitives apply.
Every answer GALEN returns carries the receipts back to the source paragraph. No invention. No ungrounded claims. If the corpus does not contain the answer, GALEN reports the gap honestly rather than hallucinating.
Every "impossible" query decomposes into some combination of these six. Each individually has been attempted somewhere. None are integrated into a single retrieval surface. GALEN composes all six.
GALEN is a routing problem dressed as a retrieval problem. The orchestrator decides which corpora and primitives a query touches, then composes the answer with citations from every source it draws on.
Below is a representative GALEN response. Every factual claim carries a PMCID citation. Contradictions across sources surface explicitly. If the corpus cannot answer, GALEN reports the gap honestly.
Above example is illustrative of GALEN response shape. Specific PMCIDs and quoted findings are representative.
GALEN serves anyone whose work requires synthesis across the biomedical literature. The query patterns differ by audience; the underlying primitives are the same.
The competitive landscape sorts into four categories, each strong in one or two areas and structurally weak in others. The defensibility argument is engineering, not data.
| Primitive / Capability | UpToDate | PubMed | Generalist LLM | Elicit / Consensus | GALEN |
|---|---|---|---|---|---|
| Section-aware retrieval | ✗ | ✗ | ✗ | ✗ | ✓ |
| Concept-graph expansion | ~ | ~ MeSH only | ✗ | ✗ | ✓ |
| Evidence-grade weighting | ✓ Editorial | ~ Filter only | ✗ | ~ | ✓ Deterministic |
| Cross-corpus fusion | ✗ | ✗ | ✗ | ✗ | ✓ |
| Temporal consensus tracking | ✗ | ✗ | ✗ | ✗ | ✓ |
| Contradiction surfacing | ✗ | ✗ | ✗ | ✗ | ✓ |
| Cited answers (no hallucination) | ✓ | n/a (no synth) | ✗ | ✓ | ✓ |
| Up-to-date with literature | ~ Months lag | ✓ | ✗ Cutoff | ✓ | ✓ Daily refresh |
| Cost (individual seat / year) | ~$499 | Free | $240 | $120-240 | $0 - $230 |
Pricing anchored to comparable biomedical information tools today, not to generalist consumer AI. Free tier non-negotiable for academic adoption.
CSR is an independent AI research lab built on a specific thesis: build research instruments that do not currently exist, optimize for coherence over speed, document the build openly. The lab has a portfolio of working systems demonstrating the methodology. GALEN is the next instrument in that portfolio, oriented for the first time toward direct external commercial use rather than purely internal research.
GALEN is engineering, not training. There is no GPU cluster requirement, no twelve-figure compute commitment. The work is parsing, indexing, retrieval orchestration, and prompt refinement. One focused founder ships v1 in approximately six months of focused work, building each phase on the validated output of the previous.
The mission is not to maximize any single product line. It is to build an institution that produces this caliber of work consistently. GALEN's path to market funds the lab. The lab will produce more instruments. Some will become products. Some will remain research output. All will be documented openly.
Create an account now to claim your slot. The free Researcher tier opens first. We'll notify you when Pro and Lab tiers begin onboarding.